TROP2

TROP2 Molekülinformation

Englischer Name	Tumor-associated calcium signal transducer 2	Anzahl der inverkehr gebrachten Arzneimittel	3
Anzahl der klinischen Arzneimittel	27	Target-Alias	Tumor-associated calcium signal transducer 2，M1S1，TROP2，TACSTD2，Pancreatic carcinoma marker protein GA733-1，Tumor Associated Calcium Signal Transducer 2，GA733-1，Membrane Component， Chromosome 1， Surface Marker 1，Gastrointestinal Tumor-Associated Antigen GA7331，Pancreatic Carcinoma Marker Protein GA7331，Cell surface glycoprotein Trop-2，Membrane component chromosome 1 surface marker 1，40kD Glycoprotein， Identified By Monoclonal Antibody GA733，Cell Surface Glycoprotein TROP2，Epithelial Glycoprotein-1，Truncated TACSTD2，GA7331，EGP-1，EGP1，GP50，Trophoblast Cell Surface Antigen 2
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Tumor-associated calcium signal transducer 2
Target-Alias	Tumor-associated calcium signal transducer 2，M1S1，TROP2，TACSTD2，Pancreatic carcinoma marker protein GA733-1，Tumor Associated Calcium Signal Transducer 2，GA733-1，Membrane Component， Chromosome 1， Surface Marker 1，Gastrointestinal Tumor-Associated Antigen GA7331，Pancreatic Carcinoma Marker Protein GA7331，Cell surface glycoprotein Trop-2，Membrane component chromosome 1 surface marker 1，40kD Glycoprotein， Identified By Monoclonal Antibody GA733，Cell Surface Glycoprotein TROP2，Epithelial Glycoprotein-1，Truncated TACSTD2，GA7331，EGP-1，EGP1，GP50，Trophoblast Cell Surface Antigen 2
Anzahl der inverkehr gebrachten Arzneimittel	3
Anzahl der klinischen Arzneimittel	27
Höchste Forschungs- und Entwicklungsphase	Approved

Produktanfrage

TROP2 Molekülalias

TROP2

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
SHR-A1921	SHR-A1921; SHRA1921; SHR-1921	Phase 3 Clinical	Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd	Solid tumours; Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Salivary Gland Neoplasms; Neoplasms; Breast Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Metastatic breast cancer; Brain metastases; Carcinoma, Non-Small-Cell Lung	Details
ESG-401	STI-3258; OQY-3258; ESG-401	Phase 3 Clinical	Shanghai Escugen Biotechnology Co Ltd	Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Metastatic breast cancer	Details
FDA018 Antibody Drug Conjugate	FDA018-ADC; FDA-018-ADC	Phase 3 Clinical	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd	Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms	Details
GQ-1010	PBI-410; GQ1010; BHV1510; BHV-1510; GQ-1010	Phase 2 Clinical	GeneQuantum Healthcare (Suzhou) Co Ltd	Solid tumours; Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung	Details
Trop2 CAR-NK cell therapy(Henan Provincial Cancer Hospital)		Phase 2 Clinical		Carcinoma, Non-Small-Cell Lung	Details
OBI-992	BSI-992; BSI992; R-992; OBI-992	Phase 2 Clinical	Boaoxin Biotechnology(Nanjing) Co Ltd	Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung	Details
JSKN-016	JSKN016; JSKN-016	Phase 2 Clinical	Jiangsu Alphamab Biopharmaceuticals Co Ltd	Solid tumours; Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung	Details
HS-20105	HS-20105; HS20105	Phase 2 Clinical	Hansoh BioMedical R&D Company	Solid tumours	Details
IBI130	IBI130; IBI-130	Phase 2 Clinical	Innovent Biologics(Suzhou) Co Ltd	Solid tumours; Neoplasm Metastasis	Details
Anti TROP2 antibody drug conjugate ADC（Fudan University）		Phase 2 Clinical	Fudan University	Triple Negative Breast Neoplasms	Details
9MW-2921	9MW2921; 9MW-2921	Phase 2 Clinical	Mabwell (Shanghai) Bioscience Co Ltd	Solid tumours	Details
MHB036C	MHB-036C	Phase 2 Clinical	Minghui Pharmaceutical Pty Ltd	Solid tumours; Neoplasms; Breast Neoplasms; Lung Neoplasms	Details
BAT-8008	BAT-8008; BAT8008	Phase 2 Clinical	Bio-Thera Solutions Ltd	Solid tumours; Triple Negative Breast Neoplasms	Details
DB-1305	DB1305; BNT325; BNT-325; DB-1305	Phase 2 Clinical	Duality Biologics (Suzhou) Co Ltd	Solid tumours	Details
BIO-106	BIO-106	Phase 2 Clinical	Hangzhou Baikai Biopharmaceutical Co Ltd	Solid tumours; Neoplasms	Details
BL-M02D1		Phase 2 Clinical	Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd	Solid tumours; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung	Details
LCB-84	LCB-84	Phase 2 Clinical	Legochem Biosciences Inc	Solid tumours	Details
JS-108	DAC-002; JS-108; DAC-002/JS108	Phase 1 Clinical	Hangzhou Dac Biotech Company Ltd	Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms	Details
IBI-3007	IBI3007; IBI-3007	Phase 1 Clinical	Innovent Biologics(Suzhou) Co Ltd	Solid tumours	Details
HS-20124	HS-20124; HS20124	Phase 1 Clinical	Hansoh BioMedical R&D Company	Solid tumours	Details
IBR-822	IBR822; IBR-822	Phase 1 Clinical	Imbioray (Hangzhou) Biomedicine Co Ltd	Solid tumours	Details
DXC-1002	DXC1002; DXC-1002	Phase 1 Clinical	Hangzhou Dac Biotech Company Ltd	Solid tumours	Details
DS-001	DS001; DS-001	Phase 1 Clinical	Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Dartsbio Pharmaceuticals Ltd	Neoplasms	Details
FZ-AD004	FZ-AD004	Phase 1 Clinical	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd	Solid tumours	Details
U87 CAR-T cell therapy(Unicar-Therapy Bio-Medicine Technology)	U-87	Phase 1 Clinical	Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd	Head and Neck Neoplasms; Solid tumours; Nasopharyngeal Neoplasms; Pancreatic Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Lung Neoplasms	Details
BCG-011	DM-001; BCG-011	Phase 1 Clinical	Biocytogen Pharmaceuticals (Beijing) Co Ltd	Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung	Details
MT-302	MT-302	Phase 1 Clinical	Myeloid Therapeutics Inc	Carcinoma; Colonic Neoplasms; Breast Neoplasms; Lung Neoplasms	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Sacituzumab govitecan	IMMU-132; TROP-2-SN-38; IMMU0132; GS-0132; IMMU-0132	Approved	Immunomedics Inc, Gilead Sciences Inc	Trodelvy, 拓达维, TRODELVY	United States	Triple Negative Breast Neoplasms	Immunomedics Inc	2020-04-22	Brain metastases; Mesothelioma; Urinary Bladder Neoplasms; Klatskin Tumor; Breast Neoplasms; Cholangiocarcinoma; Prostatic Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer; Hormone-Resistant Prostate Neoplasms; Thymoma; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Thyroid Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Solid tumours; Thyroid Carcinoma, Anaplastic; Salivary Gland Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms; Liver Failure	Details
Datopotamab deruxtecan	DS-1062a; DS-1062; Dato-DXd; S-1062a	Approved	Daiichi Sankyo Co Ltd	DATROWAY, Datroway	Japan	Breast Neoplasms	Daiichi Sankyo Co Ltd	2024-12-27	Solid tumours; Ovarian Neoplasms; Biliary Tract Neoplasms; Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis	Details
Sacituzumab tirumotecan	SKB-264; MK-2870; SKB264; sac-TMT	Approved	Klus Pharma Inc	佳泰莱	Mainland China	Triple Negative Breast Neoplasms	Sichuan Kelun-Biotech Biopharmaceutical Co Ltd	2024-11-22	Small Cell Lung Carcinoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Pancreatic Ductal; Metastatic breast cancer; Endometrial Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma; Biliary Tract Neoplasms	Details